Latest News

  • Exosomes Possible Biomarker for Targeted Sarcoma Therapy

    Researchers at The University of Kansas Cancer Center are studying tiny vesicles that may help lead to more targeted cancer therapies. Also called exosomes, these microvesicles act as “fingerprints” of a tumor’s identity, providing early clues to cancer cases.

  • First Patient Dosed with Ciclopirox Prodrug in Phase I Trial in Patients with Advanced Solid Tumors

    CicloMed LLC, a biotechnology company developing novel treatments for bladder cancer, announced that the first patient has been dosed in a Phase I clinical trial. The anti-cancer drug, called Ciclopirox Prodrug, or CPX-POM, was discovered at The University of Kansas Cancer Center. The study is characterizing the safety, dose tolerance, pharmacokinetics and pharmacodynamics in patients with advanced solid tumors.

  • KU Cancer Center named “High-Performing Site” by National Cancer Institute

    The University of Kansas Cancer Center was recently recognized as a “high-performing site” by the National Cancer Institute (NCI). Under NCI’s High-Performing Site Initiative, the program recognizes institutions that enroll a large number of patients onto National Clinical Trials Network trials while demonstrating scientific leadership in the design and conduct of clinical trials.

  • Monday Night Football Announcement: $200,000 Research Grant to Cancer Center Researcher

    Mary Markiewicz, Ph.D., assistant professor at the University of Kansas Medical Center in the Department of Microbiology, Molecular Genetics and Immunology and a researcher with KU Cancer Center, will receive the grant, made possible by a unique partnership with the Kansas City Chiefs, ESPN, the V Foundation For Cancer Research and The University of Kansas Health System.

View All


Browse by Year
2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010

Expert Care

find a doctor

Named Among US News & World Reports Best Hospitals for Cancer care 2017-18

Request an Appointment